Follicular Lymphoma ' Pipeline Review, H1 2013

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Follicular Lymphoma ' Pipeline Review, H1 2013
Published on February 2013

Report Summary


Summary

Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic development for Follicular Lymphoma, complete with latest updates, and
special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Follicular Lymphoma. Follicular Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Follicular Lymphoma.
- A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Follicular Lymphoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Follicular Lymphoma ' Pipeline Review, H1 2013 (From Slideshare) Page 1/7


Table of Content

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Follicular Lymphoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Follicular Lymphoma 9
Follicular Lymphoma Therapeutics under Development by Companies 11
Follicular Lymphoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Early Clinical Stage Products 18
Pre-Clinical Stage Products 19
Follicular Lymphoma Therapeutics ' Products under Development by Companies 20
Follicular Lymphoma Therapeutics ' Products under Investigation by Universities/Institutes 22
Companies Involved in Follicular Lymphoma Therapeutics Development 23
Bristol-Myers Squibb Company 23
F. Hoffmann-La Roche Ltd. 24
Biogen Idec Inc. 25
Sanofi-Aventis 26
Eli Lilly and Company 27
GlaxoSmithKline plc 28
Merck & Co., Inc. 29
Emergent BioSolutions Inc. 30
Reliance Life Sciences Pvt. Ltd. 31
Novartis AG 32
Cell Therapeutics, Inc. 33
Genmab A/S 34
Sandoz Inc. 35
Bayer AG 36
IMMUNOMEDICS, INC 37
MethylGene Inc 38
Accentia Biopharmaceuticals, Inc. 39
Pharmacyclics, Inc. 40
Memgen, LLC. 41
Ascenta Therapeutics, Inc. 42
CureTech Ltd. 43



Cylene Pharmaceuticals, Inc. 44
Follicular Lymphoma ' Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
obinutuzumab - Drug Profile 52
enzastaurin hydrochloride - Drug Profile 54
navitoclax - Drug Profile 56
mocetinostat - Drug Profile 58
abexinostat hydrochloride - Drug Profile 60
SAR-245409 - Drug Profile 62
BiovaxID - Drug Profile 64
ISF-35 - Drug Profile 66
BMS-936564 - Drug Profile 68
pidilizumab - Drug Profile 69
Autologous Recombinant Idiotypic Vaccine - Drug Profile 71
epratuzumab - Drug Profile 72
belinostat + [bortezomib] - Drug Profile 76
bortezomib + [cyclophosphamide] + [doxorubicin] + [prednisone] + [rituximab] + [vincristine sulfate] - Drug Profile 77
bortezomib + [rituximab] - Drug Profile 79
everolimus + panobinostat - Drug Profile 80
Therapeutic allogeneic lymphocytes program - Drug Profile 82
buparlisib - Drug Profile 83
Pixantrone + Rituximab - Drug Profile 86
mitoxantrone + bendamustine hydrochloride + [rituximab] - Drug Profile 87
AT-101 + [rituximab] - Drug Profile 88
ofatumumab - Drug Profile 90
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 94
ofatumumab + [cyclophosphamide] + [doxorubicin] + [prednisone] [INN] + [vincristine sulfate] - Drug Profile 96
epratuzumab + [rituximab] - Drug Profile 98
ocaratuzumab - Drug Profile 100
bortezomib + [cyclophosphamide] + [prednisone] + [rituximab] + [vincristine sulfate] - Drug Profile 102
denileukin diftitox + [rituximab] - Drug Profile 104
CX-5461 - Drug Profile 105
Rituximab Biosimilar - Drug Profile 107
TRU-016 + [bendamustine hydrochloride] + [rituximab] - Drug Profile 108
ABT-199 - Drug Profile 110
MK-8808 + [cyclophosphamide] + [vincristine sulfate] + [prednisolone] - Drug Profile 112
Rituximab Biosimilar - Drug Profile 114
Lenalidomide + Rituximab + Bendamustine - Drug Profile 115
Anti-CD 19 CAR Autologous PBL - Drug Profile 117
Rituximab Biosimilar + CHOP - Drug Profile 118
131I-Rituximab - Drug Profile 119
Bendamustine + Rituximab + 90Y Labelled Iburitumomab Tiuxetan - Drug Profile 120
Andrographolide - Drug Profile 121
Follicular Lymphoma Therapeutics ' Drug Profile Updates 122



Follicular Lymphoma Therapeutics ' Discontinued Products 139
Follicular Lymphoma Therapeutics - Dormant Products 140
Follicular Lymphoma ' Product Development Milestones 142
Featured News & Press Releases 142
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Tables

Number of Products Under Development for Follicular Lymphoma, H1 2013 12
Products under Development for Follicular Lymphoma ' Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Bristol-Myers Squibb Company, H1 2013 26
F. Hoffmann-La Roche Ltd., H1 2013 27
Biogen Idec Inc., H1 2013 28
Sanofi-Aventis, H1 2013 29
Eli Lilly and Company, H1 2013 30
GlaxoSmithKline plc, H1 2013 31
Merck & Co., Inc., H1 2013 32
Emergent BioSolutions Inc., H1 2013 33
Reliance Life Sciences Pvt. Ltd., H1 2013 34
Novartis AG, H1 2013 35
Cell Therapeutics, Inc., H1 2013 36
Genmab A/S, H1 2013 37
Sandoz Inc., H1 2013 38
Bayer AG, H1 2013 39
IMMUNOMEDICS, INC, H1 2013 40
MethylGene Inc, H1 2013 41
Accentia Biopharmaceuticals, Inc., H1 2013 42
Pharmacyclics, Inc., H1 2013 43
Memgen, LLC., H1 2013 44



Ascenta Therapeutics, Inc., H1 2013 45
CureTech Ltd., H1 2013 46
Cylene Pharmaceuticals, Inc., H1 2013 47
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Stage and Route of Administration, H1 2013 51
Assessment by Stage and Molecule Type, H1 2013 54
Follicular Lymphoma Therapeutics ' Drug Profile Updates 125
Follicular Lymphoma Therapeutics ' Discontinued Products 142
Follicular Lymphoma Therapeutics ' Dormant Products 143
Follicular Lymphoma Therapeutics ' Dormant Products (Contd..1) 144

List of Figures

Number of Products under Development for Follicular Lymphoma, H1 2013 12
Products under Development for Follicular Lymphoma ' Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 48
Assessment by Combination Products, H1 2013 49
Assessment by Route of Administration, H1 2013 50
Assessment by Stage and Route of Administration, H1 2013 51
Assessment by Molecule Type, H1 2013 52
Assessment by Stage and Molecule Type, H1 2013 53


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Follicular Lymphoma ' Pipeline Review, H1 2013

Recomendados

Recomendados

Mais conteúdo relacionado

Mais de ReportLinker.com

Mais de ReportLinker.com (20)

Follicular Lymphoma ' Pipeline Review, H1 2013